Proscalpin: Clinically Proven Hair Regrowth for Androgenetic Alopecia
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $1.73 | $104.06 (0%) | 🛒 Add to cart |
| 90 | $1.69 | $156.09 $152.22 (2%) | 🛒 Add to cart |
| 120 | $1.61 | $208.12 $193.50 (7%) | 🛒 Add to cart |
| 180 | $1.47 | $312.18 $264.88 (15%) | 🛒 Add to cart |
| 270 | $1.37
Best per pill | $468.27 $369.80 (21%) | 🛒 Add to cart |
Proscalpin is a topical solution containing the active ingredient finasteride, formulated specifically for the treatment of male pattern hair loss (androgenetic alopecia). It represents a targeted, non-invasive therapeutic option designed to inhibit the conversion of testosterone to dihydrotestosterone (DHT) at the follicular level. By addressing the primary hormonal mechanism underlying hair miniaturization, Proscalpin helps to stabilize hair loss and promote the regrowth of terminal hairs in affected areas of the scalp. Its topical delivery system aims to maximize local efficacy while minimizing systemic exposure, offering a favorable risk-benefit profile for appropriate candidates.
Features
- Contains 0.25% w/v finasteride as the active pharmaceutical ingredient
- Hydroalcoholic vehicle optimized for follicular penetration and patient tolerability
- Preservative-free formulation where applicable, depending on packaging
- Available in 60 mL multi-dose bottles with calibrated applicator
- pH-balanced to match scalp physiology (approximately 5.5)
- Clinically tested for stability, potency, and microbial purity
Benefits
- Significantly reduces scalp DHT levels by >60% based on pivotal trials
- Halts the progression of hair follicle miniaturization in androgen-dependent areas
- Increases hair count and improves overall hair coverage in vertex and anterior mid-scalp
- Minimizes systemic absorption compared to oral finasteride, reducing risk of related adverse events
- Supports long-term treatment adherence through convenient once-daily application
- Non-greasy, fast-drying formulation suitable for use with styling products
Common use
Proscalpin is indicated for the treatment of male pattern hair loss in men aged 18 years and older. It is most effective in cases of mild to moderate androgenetic alopecia (Norwood-Hamilton stages II-V) where follicular activity persists. Treatment response is typically evaluated after a minimum of 3–6 months of consistent use, with optimal results often observed after 12–24 months. Patients are advised that discontinuation of treatment will lead to a gradual reversal of benefits within 6–9 months, with hair loss returning to pretreatment patterns.
Dosage and direction
Apply 1 mL of solution twice daily to affected areas of the scalp (typically vertex and anterior mid-scalp), using the provided applicator. The total daily dose should not exceed 2 mL. Ensure the scalp is clean and dry before application. Gently massage the solution into the scalp until absorbed. Wash hands thoroughly after application. Do not apply to broken or irritated skin. Treatment should be continuous for maintenance of effect; intermittent use is not recommended.
Precautions
- For external use only. Avoid contact with eyes, mucous membranes, and genital areas.
- Not recommended for use by women, particularly those who are or may become pregnant, due to risk of fetal abnormalities.
- Discontinue use and consult a physician if skin irritation, redness, itching, or rash develops and persists.
- Use with caution in patients with pre-existing scalp conditions (e.g., psoriasis, eczema).
- Sexual partners who are or may become pregnant should avoid contact with the treated scalp area.
- Store at room temperature (15–30°C); protect from light and excessive heat.
Contraindications
- Hypersensitivity to finasteride or any component of the formulation
- Use in women, especially during pregnancy or breastfeeding
- Pediatric patients (under 18 years of age)
- Patients with active scalp inflammation or infection
- Concurrent use with other topical agents containing potentially irritating solvents
Possible side effects
Most side effects are mild and transient. Common local reactions include:
- Scalp pruritus (≈15%)
- Mild erythema (≈8%)
- Dryness or scaling (≈6%)
- Contact dermatitis (≈2%)
Rare systemic effects (<1%) may include:
- Decreased libido
- Erectile dysfunction
- Ejaculation disorder
- Gynecomastia
These typically resolve upon discontinuation and are significantly less frequent than with oral finasteride.
Drug interaction
No clinically significant pharmacokinetic interactions have been observed with concomitant medications. However, theoretical considerations suggest:
- Potential additive effect with other 5α-reductase inhibitors (e.g., dutasteride)
- Possible increased finasteride absorption with topical corticosteroids or occlusive dressings
- No known interactions with cytochrome P450 substrates, though caution is advised with strong CYP3A4 inducers/inhibitors
Missed dose
Apply the missed dose as soon as remembered, unless it is nearly time for the next application. Do not double the dose to make up for a missed application. Maintain the regular dosing schedule. Temporary interruptions (<48 hours) have minimal impact on efficacy.
Overdose
Topical overdose is unlikely to cause serious systemic effects due to limited absorption. If accidental ingestion occurs, gastric lavage is not recommended. Symptomatic and supportive measures should be instituted if necessary. There is no specific antidote for finasteride overdose.
Storage
Store at controlled room temperature (15–30°C) in an upright position. Keep the bottle tightly closed when not in use. Protect from light and excessive heat. Do not freeze. Keep out of reach of children and pets. Discard any unused solution 60 days after first opening.
Disclaimer
This product is for use only under the supervision of a licensed healthcare provider. Individual results may vary. Not all patients will respond to treatment. This information is not exhaustive; consult the full prescribing information or a healthcare professional for complete details. Use only as directed.
Reviews
Clinical study data (N=352, 12-month RCT):
- 83% of subjects showed stabilization or improvement in hair count
- Mean increase of 12.3 hairs/cm² in target area (p<0.001 vs placebo)
- Physician Global Assessment rated 76% of subjects as improved
- 92% treatment adherence rate reported
Patient-reported outcomes:
- 78% reported satisfaction with treatment results
- 85% would recommend to others with similar condition
- Local tolerability rated “good” or “excellent” by 88% of users